UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000002229
Receipt No. R000002731
Scientific Title Photodynamic therapy with half dose verteporfin for central serous chorioretinopathy:Prospective intervention trial
Date of disclosure of the study information 2009/07/20
Last modified on 2014/05/17 17:00:17

No. Disposal Last modified on Item of update
1 Insert 2009/07/20 23:01:38
2 Update 2009/08/30 23:12:34 UMIN ID1
3 Update 2009/08/30 23:14:12 Key inclusion criteria
4 Update 2009/08/30 23:31:41 Recruitment status
5 Update 2009/09/23 19:49:57 Key inclusion criteria
Key exclusion criteria
Key exclusion criteria
Target sample size
6 Update 2009/09/26 10:27:50 Recruitment status
7 Update 2009/11/29 18:35:17 Key inclusion criteria
Key inclusion criteria
8 Update 2009/11/29 19:01:01 Primary outcomes
Primary outcomes
Key secondary outcomes
Key secondary outcomes
9 Update 2009/11/29 19:05:38 Key inclusion criteria
10 Update 2009/11/29 19:10:35 Primary outcomes
11 Update 2009/11/29 19:11:53 Key secondary outcomes
12 Update 2009/11/29 19:13:09 Key secondary outcomes
13 Update 2009/11/29 21:04:48 Interventions/Control_1
Interventions/Control_1
14 Update 2009/11/29 21:09:57 Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Publication of results
15 Update 2009/11/29 21:22:26 Interventions/Control_1
16 Update 2009/11/29 21:30:08 Institutions
17 Update 2009/12/07 02:07:48 Target sample size
18 Update 2010/01/03 12:41:52 Key secondary outcomes
Key secondary outcomes
19 Update 2010/01/03 12:46:16 Key secondary outcomes
Key secondary outcomes
20 Update 2010/01/21 00:52:27 Primary outcomes
Primary outcomes
Key secondary outcomes
Key secondary outcomes
21 Update 2011/01/20 22:43:26 Recruitment status
22 Update 2013/01/20 10:59:58 Recruitment status
23 Update 2014/05/17 17:00:17 Email
Last name of contact person
Last name of contact person
Name of person sending information
Name of person sending information
Post marketing survey by drug manufacture etc., specified by Japanese law.


Contact us.